The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
12 2022
Historique:
received: 14 12 2021
accepted: 02 06 2022
pubmed: 22 7 2022
medline: 17 12 2022
entrez: 21 7 2022
Statut: ppublish

Résumé

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we show that ensovibep, a trispecific DARPin (designed ankyrin repeat protein) clinical candidate, can engage the three units of the spike protein trimer of SARS-CoV-2 and inhibit ACE2 binding with high potency, as revealed by cryo-electron microscopy analysis. The cooperative binding together with the complementarity of the three DARPin modules enable ensovibep to inhibit frequent SARS-CoV-2 variants, including Omicron sublineages BA.1 and BA.2. In Roborovski dwarf hamsters infected with SARS-CoV-2, ensovibep reduced fatality similarly to a standard-of-care monoclonal antibody (mAb) cocktail. When used as a single agent in viral passaging experiments in vitro, ensovibep reduced the emergence of escape mutations in a similar fashion to the same mAb cocktail. These results support further clinical evaluation of ensovibep as a broad variant alternative to existing targeted therapies for Coronavirus Disease 2019 (COVID-19).

Identifiants

pubmed: 35864170
doi: 10.1038/s41587-022-01382-3
pii: 10.1038/s41587-022-01382-3
pmc: PMC9750863
doi:

Substances chimiques

ensovibep PV6AA88RDU
Designed Ankyrin Repeat Proteins 0
Antibodies, Monoclonal 0
Combined Antibody Therapeutics 0
Antibodies, Neutralizing 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1845-1854

Informations de copyright

© 2022. The Author(s).

Références

Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020).
doi: 10.1126/science.abd0831
Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184, 3949–3961 (2021).
doi: 10.1016/j.cell.2021.06.002
Ku, Z. et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat. Commun. 12, 469 (2021).
doi: 10.1038/s41467-020-20789-7
Binz, H. K. et al. Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin
doi: 10.1080/19420862.2017.1305529
Fiedler, U. et al. MP0250, a VEGF and HGF neutralizing DARPin
doi: 10.18632/oncotarget.21738
Binz, H. K. et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 22, 575–582 (2004).
doi: 10.1038/nbt962
Walser, M. et al. Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates. Preprint at https://www.biorxiv.org/content/10.1101/2020.08.25.256339v3 (2021).
Stumpp, M. T., Dawson, K. M. & Binz, H. K. Beyond antibodies: the DARPin
doi: 10.1007/s40259-020-00429-8
Steiner, D. et al. Half-life extension using serum albumin-binding DARPin
doi: 10.1093/protein/gzx022
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
doi: 10.1038/s41586-020-2012-7
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).
doi: 10.1038/s41586-020-2179-y
Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93–116 (2019).
doi: 10.1016/bs.aivir.2019.08.002
Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol 5, 562–569 (2020).
doi: 10.1038/s41564-020-0688-y
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).
doi: 10.1016/j.cell.2020.02.058
Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114–117 (2016).
doi: 10.1038/nature16988
Walls, A. C. et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl Acad. Sci. USA 114, 11157–11162 (2017).
doi: 10.1073/pnas.1708727114
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).
doi: 10.1016/j.cell.2020.02.052
Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372–2383 (2021).
doi: 10.1016/j.cell.2021.03.013
Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57 (2021).
doi: 10.1016/j.chom.2020.11.007
Lusvarghi, S. et al. Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. J. Virol. 96, e0111021 (2022).
Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310 (2020).
doi: 10.1016/j.cell.2020.08.012
Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187 (2021).
doi: 10.1016/j.cell.2021.01.037
Wang, P. et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. Preprint at https://www.biorxiv.org/content/10.1101/2021.01.25.428137v2 (2021).
Yi, C. et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol. Immunol. 17, 621–630 (2020).
doi: 10.1038/s41423-020-0458-z
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 (2021).
doi: 10.1016/j.chom.2021.01.014
Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361 (2021).
doi: 10.1016/j.cell.2021.02.037
Gobeil, S. M.-C. et al. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science 373, eabi6226 (2021).
doi: 10.1126/science.abi6226
Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Preprint at https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1 (2020).
Voloch, C. M. et al. Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil. J. Virol. 95, e0011921 (2021).
doi: 10.1128/JVI.00119-21
Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).
doi: 10.1038/s41586-021-04387-1
Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187 (2021).
doi: 10.1016/j.cell.2021.01.037
Laffeber, C., de Koning, K., Kanaar, R. & Lebbink, J. H. G. Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants. J. Mol. Biol. 433, 167058 (2021).
doi: 10.1016/j.jmb.2021.167058
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
doi: 10.1038/s41586-021-03777-9
Copin, R. et al. In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans. Preprint at https://www.biorxiv.org/content/10.1101/2021.03.10.434834v1.full (2021).
Cathcart, A. et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. Preprint at https://www.biorxiv.org/content/10.1101/2021.03.09.434607v10 (2021).
Trimpert, J. et al. The Roborovski dwarf hamster is a highly susceptible model for a rapid and fatal course of SARS-CoV-2 infection. Cell Rep. 33, 108488 (2020).
doi: 10.1016/j.celrep.2020.108488
Walls, A. C. et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176, 1026–1039 (2019).
doi: 10.1016/j.cell.2018.12.028
Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086–3108 (2021).
doi: 10.1016/j.cell.2021.05.005
Falsey, A. R. et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med. 385, 1627–1629 (2021).
doi: 10.1056/NEJMc2113468
Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393 (2021).
doi: 10.1016/j.cell.2021.03.036
Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022).
doi: 10.1126/science.abn4947
Casalino, L. et al. Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. ACS Cent. Sci. 6, 1722–1734 (2020).
doi: 10.1021/acscentsci.0c01056
Andreano, E. et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc. Natl Acad. Sci. USA 118, e2103154118 (2021).
doi: 10.1073/pnas.2103154118
Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. 21, eabf1906 (2021).
doi: 10.1126/scitranslmed.abf1906
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
doi: 10.1038/s41586-020-2349-y
Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).
doi: 10.1038/s41586-020-2381-y
Zahradnik, J. et al. SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor. Preprint at https://www.biorxiv.org/content/10.1101/2021.01.06.425392v2 (2021).
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
doi: 10.1038/nmeth.4193
Zhang, K. Gctf: real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
doi: 10.1016/j.jsb.2015.11.003
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
doi: 10.1002/jcc.20084
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
doi: 10.1126/science.abb2507
Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Preprint at https://www.biorxiv.org/content/10.1101/2020.06.12.148296v3 (2020).
Cianfrocco, M. A., Wong, M., Youn, C. & Wagner, R. COSMIC2: a science gateway for cryo-electron microscopy structure determination. Proceedings of the Practice and Experience in Advanced Research Computing. https://doi.org/10.1145/3093338.3093390 (2017).
Chaudhury, S. et al. Benchmarking and analysis of protein docking performance in Rosetta v3.2. PLoS ONE 6, e22477 (2011).
doi: 10.1371/journal.pone.0022477
Huang, P. S. et al. RosettaRemodel: a generalized framework for flexible backbone protein design. PLoS ONE 6, e24109 (2011).
doi: 10.1371/journal.pone.0024109
Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545–574 (2011).
doi: 10.1016/B978-0-12-381270-4.00019-6
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
doi: 10.1002/pro.3235
Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS ONE 6, e25858 (2011).
doi: 10.1371/journal.pone.0025858
Torriani, G. et al. Macropinocytosis contributes to hantavirus entry into human airway epithelial cells. Virology 531, 57–68 (2019).
doi: 10.1016/j.virol.2019.02.013
Torriani, G. et al. Identification of clotrimazole derivatives as specific inhibitors of arenavirus fusion. J. Virol. 93, e01744-18 (2019).
Neerukonda, S. N. et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE 16, e0248348 (2021).
doi: 10.1371/journal.pone.0248348
Wollscheid, B. et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat. Biotechnol. 27, 378–386 (2009).
doi: 10.1038/nbt.1532
Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921 (2021).
doi: 10.1038/s41598-021-03154-6
Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001–7003 (2020).
doi: 10.1073/pnas.2002589117
Nao, N. et al. Consensus and variations in cell line specificity among human metapneumovirus strains. PLoS ONE 14, e0215822 (2019).
doi: 10.1371/journal.pone.0215822
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
doi: 10.1093/bioinformatics/btp352
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
doi: 10.1093/bioinformatics/btu170
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
doi: 10.1093/bioinformatics/btp324
Wilm, A. et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189–11201 (2012).
doi: 10.1093/nar/gks918
Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w
doi: 10.4161/fly.19695
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
doi: 10.1093/bioinformatics/btw313
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT–PCR. Euro. Surveill. 25, 2000045 (2020).
Gruber, A. D. et al. Standardization of reporting criteria for lung pathology in SARS-CoV-2-infected hamsters: what matters? Am. J. Respir. Cell Mol. Biol. 63, 856–859 (2020).
doi: 10.1165/rcmb.2020-0280LE

Auteurs

Sylvia Rothenberger (S)

Spiez Laboratory, Austrasse, Spiez, Switzerland.
Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.

Daniel L Hurdiss (DL)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Cryo-Electron Microscopy, Bijvoet Center for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Utrecht, Netherlands.

Marcel Walser (M)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Francesca Malvezzi (F)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Jennifer Mayor (J)

Spiez Laboratory, Austrasse, Spiez, Switzerland.
Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.

Sarah Ryter (S)

Spiez Laboratory, Austrasse, Spiez, Switzerland.

Hector Moreno (H)

Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.

Nicole Liechti (N)

Spiez Laboratory, Austrasse, Spiez, Switzerland.

Andreas Bosshart (A)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Chloé Iss (C)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Valérie Calabro (V)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Andreas Cornelius (A)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Tanja Hospodarsch (T)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Alexandra Neculcea (A)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Thamar Looser (T)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Anja Schlegel (A)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Simon Fontaine (S)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Denis Villemagne (D)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Maria Paladino (M)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Dieter Schiegg (D)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Susanne Mangold (S)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Christian Reichen (C)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Filip Radom (F)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Yvonne Kaufmann (Y)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Doris Schaible (D)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Iris Schlegel (I)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Christof Zitt (C)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Gabriel Sigrist (G)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Marcel Straumann (M)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Julia Wolter (J)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Marco Comby (M)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Feyza Sacarcelik (F)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Ieva Drulyte (I)

Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, Netherlands.

Heyrhyoung Lyoo (H)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.

Chunyan Wang (C)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.

Wentao Li (W)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.

Wenjuan Du (W)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.

H Kaspar Binz (HK)

Binz Biotech Consulting, Zug, Switzerland.

Rachel Herrup (R)

Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Sabrina Lusvarghi (S)

Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Sabari Nath Neerukonda (SN)

Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Russell Vassell (R)

Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Wei Wang (W)

Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Julia M Adler (JM)

Freie Universität Berlin, Institut für Virologie, Berlin, Germany.

Kathrin Eschke (K)

Freie Universität Berlin, Institut für Virologie, Berlin, Germany.

Mariana Nascimento (M)

Freie Universität Berlin, Institut für Virologie, Berlin, Germany.

Azza Abdelgawad (A)

Freie Universität Berlin, Institut für Virologie, Berlin, Germany.

Achim D Gruber (AD)

Freie Universität Berlin, Institut für Tierpathologie, Berlin, Germany.

Judith Bushe (J)

Freie Universität Berlin, Institut für Tierpathologie, Berlin, Germany.

Olivia Kershaw (O)

Freie Universität Berlin, Institut für Tierpathologie, Berlin, Germany.

Charles G Knutson (CG)

Novartis Institutes for BioMedical Research, PK Sciences, Cambridge, MA, USA.

Kamal K Balavenkatraman (KK)

Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland.

Krishnan Ramanathan (K)

Novartis Pharma AG, Basel, Switzerland.

Emanuel Wyler (E)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Luiz Gustavo Teixeira Alves (LG)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Seth Lewis (S)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Randall Watson (R)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Micha A Haeuptle (MA)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Alexander Zürcher (A)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Keith M Dawson (KM)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Daniel Steiner (D)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Carol D Weiss (CD)

Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Patrick Amstutz (P)

Molecular Partners AG, Zurich-Schlieren, Switzerland.

Frank J M van Kuppeveld (FJM)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.

Michael T Stumpp (MT)

Molecular Partners AG, Zurich-Schlieren, Switzerland. info@molecularpartners.com.

Berend-Jan Bosch (BJ)

Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.

Olivier Engler (O)

Spiez Laboratory, Austrasse, Spiez, Switzerland.

Jakob Trimpert (J)

Freie Universität Berlin, Institut für Virologie, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH